Authors:
U Schlomann, G Koller, C Conrad, T Ferdous, P Golfi, AM Garcia, S Höfling, M Parsons, P Costa, R Soper, M Bossard, T Hagemann, R Roshani, N Sewald, RR Ketchem, ML Moss, FH Rasmussen, MA Miller, DA Lauffenburger, DA Tuveson, C Nimsky, JW Bartsch
Journal name: 
Nat Commun
Citation info: 
6:6175
Abstract: 
Pancreatic ductal adenocarcinoma (PDAC) has a grim prognosis with <5% survivors after 5 years. High expression levels of ADAM8, a metalloprotease disintegrin, are correlated with poor clinical outcome. We show that ADAM8 expression is associated with increased migration and invasiveness of PDAC cells caused by activation of ERK1/2 and higher MMP activities. For biological function, ADAM8 requires multimerization and associates with β1 integrin on the cell surface. A peptidomimetic ADAM8 inhibitor, BK-1361, designed by structural modelling of the disintegrin domain, prevents ADAM8 multimerization. In PDAC cells, BK-1361 affects ADAM8 function leading to reduced invasiveness, and less ERK1/2 and MMP activation. BK-1361 application in mice decreased tumour burden and metastasis of implanted pancreatic tumour cells and provides improved metrics of clinical symptoms and survival in a Kras(G12D)-driven mouse model of PDAC. Thus, our data integrate ADAM8 in pancreatic cancer signalling and validate ADAM8 as a target for PDAC therapy.
DOI: 
http://doi.org/10.1038/ncomms7175
E-pub date: 
31 Dec 2014